Larotrectinib | TRK inhibitor
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $60.00 | ||
| 25 mg | $225.00 |
Larotrectinib (1223403-58-4) is a potent (IC50’s < 11 nM) inhibitor of tropomyosin receptor kinases A, B, and C (TrkA, B, and C).1 It is >100 fold selective against a panel of 229 kinases. Larotrectinib markedly attenuated bone cancer pain and significantly blocked the formation of neuroma-like structures and the sprouting of sensory nerve fibers. Larotrectinib caused substantial tumor regression in various cancers displaying TRK gene fusions.2-4 Larotrectinib is the first tissue agnostic drug approved by the FDA.
References/Citations:
1) Ghilardi et al. (2010), Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation, and bone cancer pain; Mol. Pain, 6 87
2) Doebele et al. (2015), An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101; Cancer Discov., 5 1049
3) Landman et al. (2018), Rapid response to Larotrectinib (LOXO-101) in Adult Chemotherapy-Naïve Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion; Clin. Breast Cancer, 18 e267
4) Drilon et al. (2018), Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children; N. Engl. J. Med., 378 731
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Larotrectinib (1223403-58-4) is a potent (IC50’s < 11 nM) inhibitor of tropomyosin receptor kinases A, B, and C (TrkA, B, and C).1 It is >100 fold selective against a panel of 229 kinases. Larotrectinib markedly attenuated bone cancer pain and significantly blocked the formation of neuroma-like structures and the sprouting of sensory nerve fibers. Larotrectinib caused substantial tumor regression in various cancers displaying TRK gene fusions.2-4 Larotrectinib is the first tissue agnostic drug approved by the FDA.
References/Citations:
1) Ghilardi et al. (2010), Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation, and bone cancer pain; Mol. Pain, 6 87
2) Doebele et al. (2015), An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101; Cancer Discov., 5 1049
3) Landman et al. (2018), Rapid response to Larotrectinib (LOXO-101) in Adult Chemotherapy-Naïve Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion; Clin. Breast Cancer, 18 e267
4) Drilon et al. (2018), Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children; N. Engl. J. Med., 378 731
Related products
-
Ketoconazole | Cytochrome P450 Inhibitor
From $45.00CAS:65277-42-1Catalog Number:10-1015Activity:Cytochrome P450 inhibitorChemical Name:(±)-1-[4-(4-{[-2-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-oneMolecular Weight:531.43Molecular Formula:C26H28Cl2N4O4Solubility:Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 20 mg/ml).Physical Properties:Off-white solidPurity:>98% by TLCStorage Temperature:RTStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT -
Sunitinib malate | VEGFR, PDGFR kinase inhibitor
From $60.00CAS:341031-54-7Catalog Number:10-1078Activity:VEGFR, PDGFR kinase inhibitorAlternate Names:SU-11248Chemical Name:N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide malateMolecular Weight:532.57Molecular Formula:C22H27FN4O4 C4H6O5Solubility:Soluble in DMSO (up to 13 mg/ml).Physical Properties:Orange solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT -
Pioglitazone HCl | PPAR gamma agonist
From $30.00CAS:112529-15-4Catalog Number:10-1010Activity:PPARγ agonistChemical Name:5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione hydrochlorideMolecular Weight:392.90Molecular Formula:C19H20N2O3S·HClSolubility:Soluble in DMSO (up to 25 mg/ml).Physical Properties:White solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:RTStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
